Journal profile · Pharmacology & Pharmacy
Expert Opinion On Drug Safety
ISSN 1474-0338 · eISSN 1744-764X · Taylor and Francis Ltd. · ENGLAND · Bimonthly · Founded 2002
Expert Opinion On Drug Safety: CAS Zone 3 · Medicine (2025 upgraded edition); impact factor 3.23; subscription journal; median 129 days to acceptance (88 articles, last 24 months); community-reported acceptance: fairly easy; 212 articles in 2025; indexed in SCIE and Scopus.
Scope
Aims, scope and focus
Expert Opinion On Drug Safety is published by Taylor and Francis Ltd. and is in Zone 3 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Pharmacovigilance and Adverse Drug Reactions, Drug-Induced Adverse Reactions and Diabetes Treatment and Management, together about 30.6% of its articles. (generated from OpenAlex topic counts and CAS ranking data)
Expert Opinion on Drug Safety ranks #62 of 216 in the Pharmacology & Pharmacy category in the 2008 ISI Journal Citation Reports. Expert Opinion on Drug Safety (ISSN 1474-0338 [print], 1744-764X [electronic]) is a MEDLINE-indexed, peer-reviewed, international journal publishing review articles on all aspects of drug safety and original papers on the clinical implications of drug treatment safety issues, providing expert opinion on the scope for future development.
Source: LetPub
Research area (LetPub): Pharmacology & Pharmacy
Main research topics OpenAlex counts of recent articles; shares are approximate
- Pharmacovigilance and Adverse Drug ReactionsPharmacology, Toxicology and Pharmaceutics18.1%
- Drug-Induced Adverse ReactionsMedicine6.4%
- Diabetes Treatment and ManagementMedicine6.1%
- Rheumatoid Arthritis Research and TherapiesMedicine4.4%
- Pharmaceutical studies and practicesMedicine4.4%
- Pharmacological Effects and Toxicity StudiesMedicine4%
- Pregnancy and Medication ImpactMedicine3.8%
- Schizophrenia research and treatmentMedicine3.6%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 3
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 3 |
| Minor | Pharmacology & Pharmacy | Zone 3 |
Top journal: noReview journal: yes
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 3
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 3 |
| Minor | Pharmacology & Pharmacy | Zone 3 |
Top journal: noReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Medicine Zone 3
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 3 |
| Minor | Pharmacology & Pharmacy | Zone 3 |
Top journal: noReview journal: yes
Database indexing
SCIEScopusLetPub
International journal early-warning lists: not listed in any editionLetPub
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor
- 3.23LetPub ·
- CiteScore 2026-06
- 6.1LetPub ·
- SJR 2026-06
- 0.86LetPub ·
- SNIP 2026-06
- 0.99LetPub ·
- h-index
- 62LetPub ·
- h-index
- 112OpenAlex ·
- i10-index
- 1,777OpenAlex ·
- 2-year mean citedness
- 3.59OpenAlex ·
- Self-citation rate
- 6.7%LetPub ·
- Share of gold OA articles
- 2.02%LetPub ·
Volume
- Articles per year
- 200LetPub ·
Articles by year OpenAlex count · 3,170 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 47 | 13 | 17 |
| 2025 | 212 | 31 | 457 |
| 2024 | 302 | 46 | 1,540 |
| 2023 | 176 | 45 | 1,688 |
| 2022 | 109 | 51 | 1,780 |
| 2021 | 170 | 45 | 2,697 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with Crossref · to
129 daysMedian, submission to acceptance · P25–P75 86 days – 173 days
- Acceptance to online
- median 28 days (88 articles)
- Submission to online
- median 164 days
- Sample
- 88 articles with submission and acceptance dates (388 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Average review time (community reports)
- 6–12 weeksLetPub ·
- Average acceptance (community reports)
- Fairly easyLetPub ·
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Subscription journalLetPub
A subscription journal: articles are read by subscription or purchase, and authors usually pay no publication charge.
No source has fee information yet; check the journal's website.
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Profile
Publication details and official links
- Publisher
- Taylor and Francis Ltd.
- Country or region
- ENGLAND
- Language
- English
- Frequency
- Bimonthly
- Founded
- 2002
- ISSN
- 1474-0338
- Electronic ISSN
- 1744-764X
- Official links
- Journal homepage ↗OpenAlex
- Submission system ↗LetPub
FAQ
Frequently asked questions about Expert Opinion On Drug Safety
What CAS zone is Expert Opinion On Drug Safety in?
In the 2025 upgraded edition of the CAS Journal Ranking, Expert Opinion On Drug Safety is in Zone 3 of Medicine, and in Zone 3 of the minor category Pharmacology & Pharmacy. In the 2026 Xinrui edition it is in Zone 3 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Expert Opinion On Drug Safety?
The latest impact factor listed by LetPub is 3.23; CiteScore 6.1, h-index 112.
How long does peer review take at Expert Opinion On Drug Safety?
Based on the dates recorded on 88 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 129 days (interquartile range 86–173 days); authors report an average review time of 6–12 weeks; the community-reported acceptance is “Fairly easy”. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
Which databases index Expert Opinion On Drug Safety?
According to LetPub and DOAJ records, Expert Opinion On Drug Safety is indexed in SCIE and Scopus.
Is Expert Opinion On Drug Safety open access, and what is the APC?
Expert Opinion On Drug Safety is a subscription journal. Fee information is not available yet; check the journal's website.
Sources and updates
The facts on this page come from LetPub, OpenAlex; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-26). Last updated: .